A Phase 1 interventional study of LY3471851 and Placebo in Systemic Lupus Erythematosus, sponsored by Nektar Therapeutics. Completed at 14 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Nektar Therapeutics · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 241st largest by enrollment of the 407 interventional ones that give a count, is one of 29 that started in 2018, is one of 104 in phase 1, and was the 266th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 29 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is close to the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
Nektar Therapeutics is the lead sponsor of 39 studies on the registry; 2 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 13 (59%) have results posted.
Nektar Therapeutics has 2 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
LY3471851 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune system back into balance.
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and immunologic effects of multiple doses of LY3471851 in participants with minimal to moderate SLE. The effects on SLE disease activity will also be evaluated. SLE participants will be randomized to receive multiple subcutaneous (SC) doses of LY3471851 or receive placebo. After receiving the last dose of LY3471851 or placebo, participants will be followed for an additional 50 days to evaluate safety, PK, pharmacodynamics (PD), and preliminary efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If a participant is taking any of the medications below for their SLE, the medication must have been administered for a minimum of 12 weeks prior to signing the ICF, and at a stable dose for a minimum of 8 weeks prior to signing the ICF:
Exclusion Criteria:
Medical Conditions:
History of cancer, apart from:
Medications:
General:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 microgram per kilogram (μg/kg) of LY3471851 or placebo on days 1, 15 and 29 by subcutaneous (SC) injection.
Drug: LY3471851 · Drug: Placebo
Participants received 6 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
Drug: LY3471851 · Drug: Placebo
Participants received 12 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
Drug: LY3471851 · Drug: Placebo
Participants received 24 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
Drug: LY3471851 · Drug: Placebo
LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Also known as: NKTR-358
The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Safety and Tolerability of LY3471851 - Number of Participants Experiencing Adverse Events
Safety and tolerability of LY3471851 as assessed through collection of adverse events, serious adverse events, change in vital signs (body temperature, blood pressure, heart rate, rate of breathing and oxygen in blood); electrocardiograms (ECG); laboratory evaluations (hematology, chemistry, liver function and urine analysis).
Time frame: Informed consent until last study visit (approximately 79 days after first dose of study drug)
Pharmacokinetics (PK): Area Under the Drug Concentration - Time Curve from Zero to the End of Dosing Interval (i.e, 14 days past each dose) (AUC[0-Day 14]) of LY3471851
PK measurement of AUC 0-Day 14
Time frame: Baseline until 14 days after last dose (approximately 43 days after first dose of study drug)
PK: Maximum Observed Drug Concentration (Cmax) of LY3471851 After First and Last Dose
PK: Measurement of Cmax
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
PK: Time to Maximum Plasma Concentration (Tmax) of LY3471851
PK: Measurement of Tmax
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
PK: Time to Decrease in Concentration of LY3471851 by Half (T1/2) Due to Elimination
PK: Measurement of T1/2
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Pharmacodynamics (PD): Measurement of Change in Number of Regulatory T Cells (Tregs) and Subsets of Tregs in Blood
PD: Measurement of Change in Number of Regulatory T Cells (Tregs) and Subsets of Tregs in Blood
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
PD: Measurement Activity of Tregs
PD: Measurement Activity of Tregs
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
PD: Measurement of Change in Number of Subsets of Conventional T Cells (Tcons) in Blood
PD: Measurement of Change in Number of Subsets of Conventional T Cells
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
PD: Measurement of Change in Number of Natural Killer Cells (NK Cells) in Blood
PD: Measurement of Change in Number of Natural Killer Cells (NK Cells) in Blood
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
PD: Measurement of Cytokines in Blood
PD: Measurement of Cytokines in Blood
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (SLEDAI): Urine; Measurement of Hematuria, Pyuria, Urinary Casts, Creatinine, Protein
Change in Disease Activity (SLEDAI): Urine; Measurement of Hematuria, Pyuria, Urinary Casts, Creatinine, Protein
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (SLEDAI): Blood: Measurement of Anti-dsDNA, Complement, White Blood Cells and Platelets
Change in Disease Activity (SLEDAI): Blood: Measurement of Anti-dsDNA, Complement, White Blood Cells and Platelets
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Physical Examination
Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Physical Examination
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Urine Analysis
Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Urine Analysis
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Blood Analysis
Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Blood Analysis
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Skin on the Body
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Skin on the Body
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Mucous Membrane
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Mucous Membrane
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Scalp
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Scalp
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Hair Loss
Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Hair Loss
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Joint score): Evaluation of Tender Joints in the Body
Change in Disease Activity (Joint score): Evaluation of Tender Joints in the Body
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Change in Disease Activity (Joint Score): Evaluation of Swollen Joints in the Body
Change in Disease Activity (Joint Score): Evaluation of Swollen Joints in the Body
Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2018 to primary completion in Aug 2019, 16 months.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 16 months is below that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rezpegaldesleukin
Lupus Erythematosus, Systemic →